Castle Biosciences Presents New Data Demonstrating DecisionDx®-SCC Complements Current Risk Assessment Methods in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck

DecisionDx-SCC is Castles prognostic 40-gene expression profile (GEP) test for patients diagnosed with high-risk cutaneous squamous cell carcinoma (SCC), designed to use a patients tumor biology to predict individual risk of metastasis for patients with SCC and one or more risk factors.